Say YES to HOPE’s Post

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution. #NYGU https://lnkd.in/e_c6ZH-g

Are you interested in learning about the difference between Alpha and Beta emitters in prostate cancer radiopharmaceuticals? Then check out this UroToday + GU OncToday interview with Alan Bryce, who discusses the decision-making process when choosing between radium-223 and lutetium-177. During the discussion, Dr. Bryce highlights the differences in cellular impact between Alpha and Beta particles, including their energy transfer and travel distance, affecting dose delivery and toxicity. https://lnkd.in/geU5Z7Uu #nuclearmedicine #radiopharmaceuticals #cancertreatment

Review presents the most recent evidence for metastatic hormone-sensitive prostate cancer treatment strategies (with focus on treatment intensification with ADT + ARPI + docetaxel) and provides guidance on applying this evidence. https://ja.ma/3JRWTXp

 A High Impact Study on Prostate Cancer Treatment https://lnkd.in/diTpz8an

In a prospective study from Fudan University Shanghai Cancer Center, involving patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone, one-third of patients showed interlesional response heterogeneity (ILRH) on PET/CT. Patients with hetero-responding disease had significantly different PFS compared to responding and non-responding groups. ILRH on both baseline and week-13 PSMA and FDG PET/CT was found to strongly associate with conventional PFS. #mCRPC #prostatecancer #abiraterone #PETCT #ILRH #PSMA #PFS #cancerresearch https://lnkd.in/ddcimiab

📢Did you hear the news? The science behind our groundbreaking prostate cancer risk assessment test, MyProstateScore 2.0 (MPS2), has been clinically validated in a new study published in JAMA Oncology! This validation underscores our commitment to accuracy and innovation in cancer diagnostics. Learn more about this game-changing advancement: https://lnkd.in/gwKU_Tun #ProstateCancer #Innovation #CancerResearch

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study https://lnkd.in/dqWzvdvE

New research reveals the dual role of mucus in pancreatic cancer, posing challenges and opportunities for treatment strategies. https://lnkd.in/gm3ccfF4 . . . . #PancreaticCancer #CancerResearch #Mucus #TherapeuticApproaches #TumorTransformation #MedicalScience #PrecisionMedicine #CancerTreatment #ResearchDiscovery #HealthcareInnovation #TumorMicroenvironment #SurvivalMechanism #DiagnosticStrategies #TumorHeterogeneity #PrecisionOncology

#PaperoftheDay: "Targeted cancer therapy: the initial high concentration may slow down the selection for resistance" DOI ⬇️ https://lnkd.in/e3zkdTXP #lungcancer #cancer #aging #rapamycin #brain #research #openaccess #peerreviewed #publishing

This post highlights the groundbreaking advancements in cancer treatment, underscoring the FDA's approval of innovative therapies like the first one-time cell therapy for solid tumors. It's exciting to see such progress benefiting patients. Looking forward to more breakthroughs in the pipeline! #CancerResearch #MedicalInnovation